The Test License for Medical Devices in India has become the essential first step for U.S. companies seeking medical device regulation, CDSCO approval, India market entry, clinical trial testing, and regulatory compliance India in 2026. This official authorization, issued by the Central Drugs Standard Control Organisation through the SUGAM portal, allows manufacturers and importers to bring in or produce small quantities of devices strictly for non-commercial purposes such as testing, evaluation, validation, clinical investigation, demonstration, or training. With India’s medical device market exploding past $15 billion, American firms are using this licence to generate local data quickly and avoid costly customs delays.
The licence is granted in two clear forms depending on the activity. For manufacturing test batches inside India, companies file Form MD-12 and receive approval in Form MD-13. For importing devices solely for testing, they use Form MD-16 and receive Form MD-17. Both routes are handled entirely online through the SUGAM portal, cutting weeks or months off the old paper-based system. The CDSCO typically issues the licence within 30 days when documents are complete, giving U.S. exporters a predictable and transparent pathway.
Key requirements are straightforward and business-friendly. Applicants must register their entity on the SUGAM portal with valid PAN and GST details, then submit a covering letter stating the exact testing objective, a device master file, a brief manufacturing or testing process description, justification for the requested quantity, and an undertaking that the facility and personnel are adequate. Fees remain low — around ₹500 per device for manufacturing and roughly $100 USD per device for imports as of April 2026 — making the licence far more affordable than full commercial approvals.
Once approved, the licence stays valid for three years. Every device must carry a clear label stating “For Testing Purposes Only – Not for Sale.” Commercial sale or distribution is strictly prohibited, and any violation can result in licence cancellation, fines, or seizure of the devices. Testing can be done at the applicant’s own facility or at a registered Medical Device Testing Laboratory if needed.
This licence matters right now because India has fully implemented mandatory licensing for nearly all medical devices, closing previous loopholes. U.S. companies that once faced long customs holds or outright rejections when shipping prototypes can now move small batches legally and generate the local clinical data required for eventual full approval. The streamlined process supports “Make in India” goals while helping American firms diversify supply chains away from over-reliance on other regions.
Experts following the sector say the test licence is a smart strategic tool. “For U.S. medtech companies, securing a Test License for Medical Devices in India is the fastest way to validate products locally, build relationships with Indian clinical partners, and stay ahead of tightening CDSCO timelines,” noted Dr. Priya Sharma, a regulatory affairs consultant advising several Fortune 500 firms. Industry reaction has been positive, with U.S. trade associations encouraging members to start applications early to avoid any backlog later in the year.
The impact on American businesses is direct and financial. Companies headquartered in Minnesota’s Medical Alley, California’s Silicon Valley, or Massachusetts’ Route 128 corridor are using the licence to lower overall development costs by running affordable local testing instead of expensive third-party labs in Europe or the United States. Smaller startups benefit the most, gaining a practical way to validate devices before committing to large-scale production or partnerships with Indian contract manufacturers. In an election year when healthcare affordability remains a top voter concern, anything that helps control device costs draws attention from both industry leaders and policymakers.
The CDSCO has already signaled further upgrades to the SUGAM portal later in 2026, including AI-assisted application reviews and real-time tracking. U.S. companies that obtain the Test License for Medical Devices in India now will be best positioned to capitalize on upcoming policy changes and potential trade incentives. With summer industry events in Chicago and Boston already featuring dedicated sessions on the Indian pathway, the window for smart, strategic market entry is wide open.
By Sam Michael
Follow us and subscribe now — turn on push notifications to never miss a breaking U.S. news update. Join our WhatsApp channel and social media pages for real-time alerts.